MCID: KRT001
MIFTS: 62

Keratoconjunctivitis Sicca

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

MalaCards integrated aliases for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 77 54 30 56 45 15 17 74
Keratitis Sicca 54 74
Xerophthalmia 54 74
Dry Eye Syndromes 74
Dry Eye Syndrome 54
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 45 D007638
SNOMED-CT 69 78946008

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to sjogren syndrome and dry eye syndrome, and has symptoms including eye manifestations, dryness of eye and dacryops. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and bone, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 77 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 sjogren syndrome 33.7 HSPG2 LTF TRIM21
2 dry eye syndrome 32.6 IL6 LTF NGF TNF
3 keratoconjunctivitis 32.5 IL4 NGF TNF
4 subacute cutaneous lupus erythematosus 30.5 TNF TRIM21
5 acute respiratory distress syndrome 30.2 IL1B IL6 TNF
6 uveitis 30.2 IL10 IL1A IL4 TNF
7 sleep apnea 30.1 IL1B IL6 TNF
8 juvenile rheumatoid arthritis 30.1 IL1B IL6 TNF
9 sialadenitis 30.0 HSPG2 TNF TRIM21
10 chronic graft versus host disease 30.0 ALB CD79A IL10 IL1A TNF
11 irritant dermatitis 30.0 IL1A IL1B TNF
12 arthritis 29.9 IL10 IL1A IL1B IL6 TNF
13 myeloma, multiple 29.9 ALB CD79A IL6 TNF
14 hematopoietic stem cell transplantation 29.7 IL10 IL6 TNF
15 graft-versus-host disease 29.7 IL10 IL1A IL1B IL6 TNF
16 arteries, anomalies of 29.6 ALB IL1B IL6 TNF
17 dengue shock syndrome 29.5 IL1B IL6 TNF
18 peritonitis 29.3 ALB IL10 IL1B IL6 TNF
19 autoimmune disease 29.2 IL10 IL1B IL4 IL6 TNF
20 aspergillosis 29.2 IL10 IL4 TLR4 TNF
21 bacterial sepsis 29.2 IL10 TLR4 TNF
22 chronic fatigue syndrome 29.2 IL10 IL1B IL6 TNF
23 appendicitis 29.1 ALB IL10 IL1B IL6 TNF
24 rheumatoid arthritis 29.0 IL10 IL1A IL1B IL4 IL6 TLR4
25 colitis 28.9 IL10 IL1B IL4 IL6 TLR4 TNF
26 chlamydia 28.4 CD79A IL10 IL1A IL1B IL4 IL6
27 myocardial infarction 28.2 ALB IL10 IL1B IL6 TLR4 TNF
28 otitis media 28.2 ALB CD79A IL10 IL1B IL4 IL6
29 systemic lupus erythematosus 27.4 ALB CD79A IL10 IL1B IL4 IL6
30 xerophthalmia 12.8
31 aplasia of lacrimal and salivary glands 11.7
32 myelopathy, htlv-1-associated 11.4
33 tropical spastic paraparesis 11.4
34 retrovirus-associated myelopathy 11.4
35 kenny-caffey syndrome, type 1 11.3
36 kenny-caffey syndrome, type 2 11.1
37 keratoconus posticus circumscriptus 11.1
38 premature ovarian failure 1 11.0
39 keratomalacia 10.7
40 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.6
41 japanese encephalitis 10.4
42 chronic follicular conjunctivitis 10.4 IL1A IL1B
43 idiopathic inflammatory myopathy 10.4 IL1A TRIM21
44 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
45 critical limb ischemia 10.4 IL6 TNF
46 autoimmune myocarditis 10.3 IL6 TNF
47 leukomalacia 10.3 IL6 TNF
48 scorpion envenomation 10.3 IL6 TNF
49 streptococcal toxic-shock syndrome 10.3 IL6 TNF
50 membranous nephropathy 10.3 ALB CD79A TNF

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


eye manifestations, dryness of eye, dacryops

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ALB CD79A ERBB2 ERBB3 HSPG2 IL10
2 immune system MP:0005387 10.35 CD79A CLEC4F ERBB3 HSPG2 IL10 IL1A
3 hematopoietic system MP:0005397 10.32 CD79A CLEC4F HSPG2 IL10 IL1A IL1B
4 cardiovascular system MP:0005385 10.29 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
5 cellular MP:0005384 10.28 ALB CD79A ERBB2 ERBB3 HSPG2 IL10
6 behavior/neurological MP:0005386 10.26 ERBB2 ERBB3 HSPG2 IL10 IL6 NGF
7 integument MP:0010771 10.23 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
8 digestive/alimentary MP:0005381 10.22 ALB ERBB2 ERBB3 HSPG2 IL10 IL4
9 mortality/aging MP:0010768 10.22 ALB ERBB2 ERBB3 HSPG2 IL10 IL1B
10 liver/biliary system MP:0005370 10.09 ALB CD79A HSPG2 IL10 IL4 IL6
11 muscle MP:0005369 10.07 ALB ERBB2 ERBB3 HSPG2 IL10 IL6
12 neoplasm MP:0002006 10.06 ALB CD79A ERBB2 ERBB3 IL10 IL1A
13 nervous system MP:0003631 10.03 CD79A ERBB2 ERBB3 HSPG2 IL10 IL1B
14 normal MP:0002873 9.81 ALB CD79A ERBB2 ERBB3 IL10 IL4
15 respiratory system MP:0005388 9.56 ERBB2 ERBB3 HSPG2 IL10 IL4 IL6
16 vision/eye MP:0005391 9.23 HSPG2 IL10 IL4 IL6 NGF NRTN

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
3
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
4
Povidone Approved Phase 4,Phase 2,Phase 1,Not Applicable 9003-39-8
5
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
6
tannic acid Approved Phase 4,Not Applicable 1401-55-4
7
Pseudoephedrine Approved Phase 4 90-82-4 7028
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Dipivefrin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52365-63-6 3105
10
Travoprost Approved Phase 4 157283-68-6 5282226
11
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
12
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
13
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
14
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
15
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
16
Tobramycin Approved, Investigational Phase 4,Phase 1,Not Applicable 32986-56-4 36294 5496
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
19
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
20
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
21
Fluorometholone Approved, Investigational Phase 4,Phase 3,Not Applicable 426-13-1 9878
22
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
23
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
24
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
25
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
26
Menthol Approved Phase 4 2216-51-5 16666
27
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
28
Azithromycin Approved Phase 4 83905-01-5 447043 55185
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 83-43-2 6741
30
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1 302-25-0
31
Ofloxacin Approved Phase 4,Not Applicable 82419-36-1 4583
32
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-24-8 5755
34
Levofloxacin Approved, Investigational Phase 4,Not Applicable 100986-85-4 149096
35
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
36
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
37
Timolol Approved Phase 4,Phase 3 26839-75-8 5478 33624
38
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
39
Latanoprost Approved, Investigational Phase 4,Phase 3,Not Applicable 130209-82-4 5311221 5282380
40
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
41
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
42
Sulfacetamide Approved Phase 4 144-80-9 5320
43
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 564-25-0 54671203
46
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
47
Doxazosin Approved Phase 4 74191-85-8 3157
48
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
49
Oxybutynin Approved, Investigational Phase 4,Not Applicable 5633-20-5 4634
50
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2

Interventional clinical trials:

(show top 50) (show all 916)
# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
8 An Open Label Comparing the Short Term Efficacy of Lacrisert Unknown status NCT03079271 Phase 4 Lacrisert, 5 Mg Ophthalmic Insert
9 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
10 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
11 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
12 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
13 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
14 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
15 The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
16 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
17 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
18 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
19 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
20 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
21 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
22 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
23 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
24 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
25 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
26 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
27 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
28 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
29 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
30 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
31 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
32 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
33 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
34 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
35 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
36 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
37 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
38 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
39 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
40 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
42 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
43 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
44 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
45 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
46 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
47 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
48 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
49 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
50 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

# Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 30

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

42
Eye, Salivary Gland, Bone, Testes, Thyroid, T Cells, B Cells

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 394)
# Title Authors Year
1
Phenotypic features and predictors of the clinical severity of keratoconjunctivitis sicca and salivary gland dysfunction in patients with Sjögren's syndrome: a longitudinal analysis of the Korean Initiative of primary Sjögren's Syndrome (KISS) cohort. ( 30475093 )
2019
2
Assessment of meibomian gland morphology by noncontact infrared meibography in Shih Tzu dogs with or without keratoconjunctivitis sicca. ( 30715776 )
2019
3
Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca. ( 30724448 )
2019
4
Apricot Kernel Extract and Amygdalin Inhibit Urban Particulate Matter-Induced Keratoconjunctivitis Sicca. ( 30759852 )
2019
5
Characterisation of corneal impression cytology in dogs and its application in the diagnosis of keratoconjunctivitis sicca. ( 31019006 )
2019
6
Revisiting Keratoconjunctivitis sicca (KCS) associated with Human T-Cell Lymphotropic Virus Type 1 (HTLV-1): prevalence, clinical aspects and proviral load. ( 31059675 )
2019
7
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2019
8
Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome. ( 30025146 )
2018
9
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
10
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
11
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
12
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 61 Grafts. ( 29864431 )
2018
13
Rheumatoid factor isotype and Ro epitope distribution in primary Sjögren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. ( 29936570 )
2018
14
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
15
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
16
Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. ( 29995121 )
2018
17
Oral omega 3 in different proportions of EPA, DHA, and antioxidants as adjuvant in treatment of keratoconjunctivitis sicca in dogs. ( 30208145 )
2018
18
Severity of Sjögren's Syndrome Keratoconjunctivitis Sicca Increases with Increased Percentage of Conjunctival Antigen-Presenting Cells. ( 30223431 )
2018
19
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2018
20
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
21
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
22
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
23
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
24
Assessment of tear film osmolarity using the TearLab™ osmometer in normal dogs and dogs with keratoconjunctivitis sicca. ( 27761982 )
2017
25
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2017
26
Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. ( 28218751 )
2017
27
Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca. ( 29038779 )
2017
28
Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits. ( 29038781 )
2017
29
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2017
30
A novel treatment for keratitis sicca (Dry eye): Anatomical feasibility study. ( 28631333 )
2017
31
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
32
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
33
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
34
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
35
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
36
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
37
Erratum to: Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27919262 )
2016
38
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
39
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
40
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
41
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. ( 26628876 )
2015
42
Infrared ocular thermography in dogs with and without keratoconjunctivitis sicca. ( 23905697 )
2015
43
Retrospective study of the prevalence of keratoconjunctivitis sicca in diabetic and nondiabetic dogs after phacoemulsification. ( 25429857 )
2015
44
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. ( 25664315 )
2015
45
Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. ( 25675975 )
2015
46
Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. ( 25747049 )
2015
47
Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. ( 25802852 )
2015
48
Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management. ( 30101119 )
2015
49
Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. ( 26466228 )
2015
50
Salivary gland scintigraphy in patients suffering from severe keratoconjunctivitis sicca. Evaluation of the viability of submandibular glands before and after transfer into the temporal fossa. ( 26083667 )
2015

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

Pathways related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CD79A ERBB2 ERBB3 IL10 IL1A IL1B
2
Show member pathways
13.9 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
3
Show member pathways
13.73 ERBB2 ERBB3 IL10 IL1A IL1B IL4
4
Show member pathways
13.59 ERBB2 ERBB3 IL10 IL1A IL1B IL4
5
Show member pathways
13.44 ERBB2 ERBB3 IL10 IL1A IL1B IL4
6
Show member pathways
13.38 ERBB2 ERBB3 IL10 IL1A IL1B IL4
7
Show member pathways
13.36 ERBB2 IL10 IL1A IL1B IL4 IL6
8
Show member pathways
13.28 CD79A ERBB2 ERBB3 IL1A IL1B IL4
9
Show member pathways
13.05 ERBB2 ERBB3 IL4 IL6 NGF TLR4
10
Show member pathways
12.93 IL10 IL1A IL1B IL4 IL6 TNF
11 12.84 ERBB2 ERBB3 IL1A IL1B NGF TNF
12
Show member pathways
12.78 IL1A IL1B IL6 NGF TLR4 TNF
13
Show member pathways
12.66 IL1A IL1B NGF TLR4 TNF
14
Show member pathways
12.65 ERBB2 IL10 IL1B IL6 TNF
15
Show member pathways
12.64 IL10 IL1A IL1B IL4 IL6 TNF
16 12.62 CD79A IL10 IL1B IL4 TNF
17
Show member pathways
12.62 IL10 IL1A IL1B IL4 IL6 TLR4
18
Show member pathways
12.46 ERBB2 ERBB3 IL1A IL1B
19
Show member pathways
12.42 ALB IL1B IL4 IL6 TNF
20
Show member pathways
12.39 HSPG2 IL1A IL1B IL6 TLR4 TNF
21
Show member pathways
12.37 IL1B IL4 IL6 TNF
22 12.37 ERBB2 ERBB3 HSPG2 TLR4 TNF
23
Show member pathways
12.31 IL1A IL6 TLR4 TNF
24
Show member pathways
12.31 IL10 IL1A IL1B IL4 TLR4 TNF
25
Show member pathways
12.28 IL10 IL1A IL1B IL4 IL6 NGF
26
Show member pathways
12.27 IL1A IL1B IL6 TNF
27
Show member pathways
12.27 IL1B IL4 IL6 TLR4 TNF
28
Show member pathways
12.26 IL10 IL1B IL6 TNF
29
Show member pathways
12.26 IL1A IL1B TLR4 TNF
30 12.24 IL10 IL1A IL1B IL6 TLR4 TNF
31 12.17 IL10 IL1A IL1B IL6 NGF TNF
32
Show member pathways
12.16 IL10 IL1A IL1B IL4 IL6 NGF
33
Show member pathways
12.15 IL10 IL1B IL6 TLR4 TNF
34
Show member pathways
12.12 ERBB2 ERBB3 IL1A IL1B TLR4
35 12.09 CD79A IL10 IL4 IL6 TNF
36
Show member pathways
12.03 HSPG2 IL1B IL4 IL6 TLR4 TNF
37 12 IL1A IL1B IL6 TNF
38 11.98 IL1A IL1B IL4 IL6 TNF
39 11.96 IL10 IL1B IL6 TLR4 TNF
40 11.96 IL1A IL1B IL4 IL6 TLR4 TNF
41 11.93 IL1A IL1B IL6 TLR4
42 11.93 IL1A IL1B IL6 TLR4 TNF
43 11.92 ERBB2 IL6 TLR4
44 11.91 IL1B TLR4 TNF
45 11.9 IL10 IL1A IL1B IL4 IL6 TNF
46 11.88 IL10 IL1B IL4 TNF
47 11.84 IL10 IL1B IL6 TNF
48 11.76 IL1B IL4 IL6 TNF
49
Show member pathways
11.76 IL1A IL1B IL6 TNF
50 11.74 IL10 IL1B IL4 IL6 TNF

GO Terms for Keratoconjunctivitis Sicca

Cellular components related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ALB ERBB3 HSPG2 IL10 IL1A IL1B
2 extracellular region GO:0005576 9.4 ALB ERBB3 HSPG2 IL10 IL1A IL1B

Biological processes related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 IL1B LTF TLR4 TNF
2 immune response GO:0006955 9.98 IL10 IL1A IL1B IL4 IL6 TLR4
3 MAPK cascade GO:0000165 9.97 ERBB2 ERBB3 IL1B NRTN TNF
4 cytokine-mediated signaling pathway GO:0019221 9.93 IL10 IL1A IL1B IL4 IL6 TNF
5 cellular response to lipopolysaccharide GO:0071222 9.91 IL10 IL1B IL6 TLR4 TNF
6 defense response to Gram-negative bacterium GO:0050829 9.89 IL6 LTF TLR4
7 positive regulation of JNK cascade GO:0046330 9.89 IL1B TLR4 TNF
8 B cell differentiation GO:0030183 9.89 CD79A IL10 IL4
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 ERBB2 ERBB3 NGF NRTN
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL1B IL6 LTF TLR4 TNF
11 positive regulation of T cell proliferation GO:0042102 9.87